GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +1.84% /zigman2/quotes/200381158/delayed UK:GSK +1.54% was downgraded to neutral from buy at UBS, which said the European pharma sector is cheap -- trading at a double-digit discount to the market on forward price-to-earnings -- but not a bargain, since earnings per share are seen growing 8% next year vs. about 30% for the broader market. On Glaxo in particular, UBS said investors will gravitate toward a sum-of-the-parts valuation until things are clearer on the separation of its consumer health joint venture with Pfizer /zigman2/quotes/202877789/composite PFE +0.56% . UBS said its top European pharma picks are Novartis /zigman2/quotes/203286410/delayed CH:NOVN -1.68% , Bayer /zigman2/quotes/206842998/delayed XE:BAYN -0.48% and H. Lundbeck /zigman2/quotes/208724881/delayed DK:LUN -1.02% .

















